Deutsche Bank AG lessened its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) by 4.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,262 shares of the biopharmaceutical company’s stock after selling 4,247 shares during the quarter. Deutsche Bank […]
Rhumbline Advisers boosted its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) by 7.8% during the second quarter, Holdings Channel.com reports. The firm owned 217,848 shares of the biopharmaceutical company’s stock after acquiring an additional 15,775 shares during the quarter. Rhumbline Advisers’ holdings in Cytokinetics were worth $8,559,000 as of its most recent SEC filing. […]